Healthcare Industry News: drug eluting balloon
News Release - January 29, 2010
Invatec Comments on First Clinical Results of Drug Eluting Balloon Technology for Below the Knee (BtK)More than 50% Reduction of Restenosis Rate Compared to Standard PTA
LEIPZIG, Germany--(HSMN NewsFeed)--Invatec, a comprehensive innovator of interventional products, welcomed the first clinical results of the drug eluting balloon (DEB), IN.PACT Amphirion, for complex Critical Limb Ischemia (CLI) in Below the Knee (BtK). As Dr. Andrej Schmidt, leading investigator from the Park Hospital Leipzig, reported during the LINC congress, preliminary results indicate a dramatic reduction in restenosis rate by application of the drug eluting balloon. “In our experience, 69% of Clinical Limb Ischemia patients with long lesions show restenosis after 3 months. The drug eluting balloon was able to bring this number down to 31%. Considering the mean lesion lengths of 17 cm and 58% rate of total occlusions prior to intervention, these results have the potential to change the way we treat complex CLI.” Prof. Dr. Dierk Scheinert, chief physician of the Angiology Department at the Park-Hospital Leipzig and principal investigator of the IN.PACT Amphirion register, added: “It took us several years to develop adequate techniques to successfully re-open BtK arteries but we had no means of preventing restenosis for longer arterial segments. Drug eluting stents are only feasible in short lesions. The drug eluting balloon is the first method that brings down restenosis rates in those complex CLI cases. An interesting observation is also the nature of the restenosis, if it appears after treatment with DEB: we see focal segments, not re-narrowing along the total artery. This makes re-intervention less complex.”
Stefan Widensohler and Andrea Venturelli, co-founders of Invatec, welcomed the trial results: “This is the first data point on the use of drug eluting balloons for complex Below the Knee applications, and it is a very positive data point. We feel encouraged to proceed with our high-level clinical trial program on DEB which will provide even more definitive proof that drug eluting balloons can benefit patients with arterial disease in the coronaries, in hemodialysis shunts and throughout the entire leg.”
INVATEC has initiated several clinical trials to assess their IN.PACT DEB line which includes 4 different balloon platforms. drug eluting balloons have the ability to deliver Paclitaxel to the vessel wall and inhibit tissue growth within the artery, a factor that leads to the re-narrowing of arteries. Previous trials conducted on the SFA and coronary arteries have shown outcomes favoring drug eluting balloons.
Headquartered in Italy and with manufacturing in Italy and Switzerland, Invatec is one of the world’s fastest growing companies in the design, development and production of interventional cardiology and peripheral vascular products for the treatment of coronary and peripheral arterial disease. Driven by research and technology, Invatec actively collaborates with physicians and centres of excellence to develop products that will improve life expectancy and quality of life for patients. Vertically integrated, Invatec also has the in-house ability to design, develop, manufacture and assemble its entire product offering from raw materials. As a result, the company has one of the largest therapeutic catheter product lines in the world, including 10 stent platforms, 7 angioplasty balloon platforms, 4 drug eluting balloon platforms and accessory devices, now sold in over 70 countries.
Dedicated to "making ideas come alive," the company was founded in 1996 by Andrea Venturelli and Stefan Widensohler, and has grown to almost 1,000 employees.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.